These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38936704)

  • 1. Continuous theta burst stimulation for bipolar depression: A multicenter, double-blind randomized controlled study exploring treatment efficacy and predictive potential of kynurenine metabolites.
    Dellink A; Hebbrecht K; Zeeuws D; Baeken C; De Fré G; Bervoets C; De Witte S; Sabbe B; Morrens M; Coppens V
    J Affect Disord; 2024 Sep; 361():693-701. PubMed ID: 38936704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary assessment of the therapeutic efficacy of continuous theta-burst magnetic stimulation (cTBS) in major depression: a double-blind sham-controlled study.
    Chistyakov AV; Kreinin B; Marmor S; Kaplan B; Khatib A; Darawsheh N; Koren D; Zaaroor M; Klein E
    J Affect Disord; 2015 Jan; 170():225-9. PubMed ID: 25261629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does escitalopram reduce neurotoxicity in major depression?
    Halaris A; Myint AM; Savant V; Meresh E; Lim E; Guillemin G; Hoppensteadt D; Fareed J; Sinacore J
    J Psychiatr Res; 2015; 66-67():118-26. PubMed ID: 26009299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase-and disorder-specific differences in peripheral metabolites of the kynurenine pathway in major depression, bipolar affective disorder and schizophrenia.
    Brum M; Nieberler M; Kehrwald C; Knopf K; Brunkhorst-Kanaan N; Etyemez S; Allers KA; Bittner RA; Slattery DA; McNeill RV; Reif A; Kittel-Schneider S
    World J Biol Psychiatry; 2023; 24(7):564-577. PubMed ID: 36648064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
    Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
    PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive continuous theta burst stimulation for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled studies.
    Cai DB; Qin XD; Qin ZJ; Lan XJ; Wang JJ; Ng CH; Zheng W; Xiang YT
    J Affect Disord; 2024 Feb; 346():266-272. PubMed ID: 37924984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Continuous Theta Burst "Intensive" Stimulation in Acute-Phase Bipolar Depression: A Pilot, Exploratory Study.
    Mallik G; Mishra P; Garg S; Dhyani M; Tikka SK; Tyagi P
    J ECT; 2023 Mar; 39(1):28-33. PubMed ID: 35815855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Active vs Sham Intermittent Theta Burst Transcranial Magnetic Stimulation for Patients With Bipolar Depression: A Randomized Clinical Trial.
    McGirr A; Vila-Rodriguez F; Cole J; Torres IJ; Arumugham SS; Keramatian K; Saraf G; Lam RW; Chakrabarty T; Yatham LN
    JAMA Netw Open; 2021 Mar; 4(3):e210963. PubMed ID: 33710288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous theta burst stimulation over the supplementary motor area in refractory obsessive-compulsive disorder treatment: A randomized sham-controlled trial.
    Harika-Germaneau G; Rachid F; Chatard A; Lafay-Chebassier C; Solinas M; Thirioux B; Millet B; Langbour N; Jaafari N
    Brain Stimul; 2019; 12(6):1565-1571. PubMed ID: 31383594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
    Savitz J; Drevets WC; Smith CM; Victor TA; Wurfel BE; Bellgowan PS; Bodurka J; Teague TK; Dantzer R
    Neuropsychopharmacology; 2015 Jan; 40(2):463-71. PubMed ID: 25074636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers.
    Dahl J; Andreassen OA; Verkerk R; Malt UF; Sandvik L; Brundin L; Ormstad H
    Psychoneuroendocrinology; 2015 Jun; 56():12-22. PubMed ID: 25770856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
    Savitz J; Dantzer R; Wurfel BE; Victor TA; Ford BN; Bodurka J; Bellgowan PS; Teague TK; Drevets WC
    Psychoneuroendocrinology; 2015 Feb; 52():200-11. PubMed ID: 25486577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral theta burst stimulation for patients with acute unipolar or bipolar depressive episodes: A systematic review of randomized controlled studies.
    Qin ZJ; Huang SQ; Lan XJ; Shi ZM; Huang XB; Ungvari GS; Jackson T; Zheng W; Xiang YT
    J Affect Disord; 2023 Nov; 340():575-582. PubMed ID: 37579881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated sequential bilateral theta-burst stimulation in major depression: an open trial.
    Ramasubbu R; Brown EC; Selby B; McGirr A; Cole J; Hassan H; McAusland L
    Eur Arch Psychiatry Clin Neurosci; 2024 Apr; 274(3):697-707. PubMed ID: 37470840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of major depressive disorder with bilateral theta burst stimulation: study protocol for a randomized, double-blind, placebo-controlled multicenter trial (TBS-D).
    Plewnia C; Brendel B; Schwippel T; Nieratschker V; Ethofer T; Kammer T; Padberg F; Martus P; Fallgatter AJ
    Eur Arch Psychiatry Clin Neurosci; 2021 Oct; 271(7):1231-1243. PubMed ID: 34146143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial.
    Plewnia C; Pasqualetti P; Große S; Schlipf S; Wasserka B; Zwissler B; Fallgatter A
    J Affect Disord; 2014 Mar; 156():219-23. PubMed ID: 24411682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
    Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
    Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Ning Y
    Psychoneuroendocrinology; 2019 Mar; 101():72-79. PubMed ID: 30419374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
    Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
    Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies.
    Marx W; McGuinness AJ; Rocks T; Ruusunen A; Cleminson J; Walker AJ; Gomes-da-Costa S; Lane M; Sanches M; Diaz AP; Tseng PT; Lin PY; Berk M; Clarke G; O'Neil A; Jacka F; Stubbs B; Carvalho AF; Quevedo J; Soares JC; Fernandes BS
    Mol Psychiatry; 2021 Aug; 26(8):4158-4178. PubMed ID: 33230205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.